Neoadjuvant GW572016 to Treat Breast Cancer

计划入组 49 人 · 首次发布于 2005 年 9 月 21 日

INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients

首次发布于 2007 年 4 月 3 日

Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

计划入组 120 人 · 首次发布于 2009 年 2 月 12 日

Trastuzumab emtansine(Kadcyla)

Rx

HER2+ Breast Cancer(Diakonos)

oncology program (HER2+ breast cancer)

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

International Breast Cancer Research Foundation

United States

FDA Approves HERCESSI™ (trastuzumab-strf) as Biosimilar to Herceptin for HER2-Overexpressing Cancers

Accord BioPharma's Hercessi (trastuzumab-strf) Receives FDA Approval for 420mg Strength

FDA Approves Ontruzant, Samsung Bioepis and Merck's Biosimilar to Herceptin for Cancer Treatment